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Abstract41
Background: Measuring patient-centered outcomes in clinical practice is valuable for monitoring42
patients and advancing real-world research. A new initiative from the Harmonising Outcome43
Measures for Eczema (HOME) group aims to recommend what might be recorded for atopic eczema44
(AE) patients in routine clinical care.45
Objectives: Prioritize outcome domains to measure AE in clinical practice and select valid and46
practical outcome measurement instruments for the highest-priority domain.47
Methods: An online survey of HOME members identified and ranked 21 possible health-domains.48
Suitable instruments were then selected for the top-prioritized domain at the HOME VI meeting,49
using established consensus processes informed by systematic reviews of instrument quality.50
Results: Patient-reported symptoms was the top-prioritized domain. Based on psychometric51
properties and feasibility, there was consensus that the recommended instruments to measure AE52
symptoms in clinical practice are the Patient-Oriented Eczema Measure (POEM) and/or the Patient-53
Oriented SCORing Atopic Dermatitis index (PO-SCORAD). The Numerical Rating Scale for itch54
received support pending definition and validation in AE.55
Conclusion: Following the first step of the HOME Clinical Practice initiative, we endorse using the56
POEM, the PO-SCORAD, or both for measuring AE symptoms in clinical practice. Additional high-57
priority domains for clinical practice will be assessed at subsequent HOME meetings.58
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Introduction.59
Atopic eczema (AE) (syn. atopic dermatitis) is a common chronic inflammatory skin disease1–3 which60
causes a significant burden on the life of patients.4–6 In daily practice, most clinicians assess their61
patients using a detailed history and physical examination. While invaluable for the practicing62
clinician, such assessments do not quantitatively capture multiple domains of the disease over time.63
Adding outcome measurement using well-validated instruments to patient management can be64
useful at the individual level for monitoring treatment response or assessing the disease burden.65
Some outcomes, such as patient-reported outcomes (PROs), can be collected outside of scheduled66
office visits thus enhancing the understanding of the patient’s disease in between office visits. A67
study in patients with cancer found that simply monitoring symptoms using PRO instruments68
imparted clinical benefit to patients,7 even improving survival.869
Outcome measurements collected in the clinical practice are also an important part of real-world70
data (RWD), collectively defined as the data relating to patient health status and/or the delivery of71
health care routinely collected from a variety of sources.9 RWD has been gaining traction as a key72
resource for improving patient care, by translating it into actionable information that benefits73
healthcare and patient outcomes,10 for example assisting in developing guidelines and decision74
support tools for use in clinical practice.75
The past years have seen renewed interest in the use of RWD to bridge the evidentiary gap between76
clinical research and practice.11 Real-world research includes patients representative of diverse77
populations and evaluates interventions realistically.10 RWD with outcome measurements can78
advance our understanding of the natural history and burden of disease, treatment patterns,79
compliance, persistence, and health outcomes of different treatments.12 RWD can be applied to80
support clinical trial designs (e.g., pragmatic clinical trials) and observational studies to generate81
innovative, new treatment approaches.9 Last, outcome measurement can inform quality-of-care82
improvement projects - eventually leading to improved treatment of patients.83
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There are currently no recommendations to guide the selection of instruments for measuring PROs84
in AE in clinical practice. To attain high-quality outcome measurement data, standardized and85
validated outcomes measurements are needed. This is critical for research initiatives, especially86
when aggregating data across centers, performing meta-analyses, or analysing trends at a87
population level. The Harmonising Outcome Measures for Eczema (HOME) group is a global initiative88
working towards standardization and validation of outcome measurement in AE. Since 2012, the89
HOME group has focused primarily on clinical trials.13–16 Because the needs and available resources90
in daily practice are different than in clinical trials, an adaptation of the current HOME clinical trial91
initiative is needed to fill such a gap. The HOME Clinical Practice Set aims to identify instruments to92
measure domains of health in patients with AE suitable for use in the clinical practice setting.93
The HOME Executive Committee agreed that the HOME Clinical Practice Set should follow a similar94
process as the original HOME Roadmap- a step-by-step process of identifying selected outcome95
domains followed by systematically identifying the appropriate measurement instruments for these96
domains.17 The Executive Committee also agreed that the Clinical Practice Set will not be a97
mandatory core outcome set (COS) containing a predefined number of outcome domains and their98
measurement instruments that need to be measured in all patients, as is the case with the clinical99
trial COS. Instead, there is no limit to the number of domains identified to be important to measure100
in the HOME Clinical Practice Set. While COS allow for complete and harmonized data sets, their101
adoption in clinical practice is challenging due to time and budgetary constraints. Patient burden,102
defined by PCORI as the time, effort, and emotional strain associated with completing a PROM,18 is103
another limitation, and effort should be made to minimize this burden.104
To further enhance flexibility, it was decided the HOME Clinical Practice Set will include all105
instruments (not just one as in the core set for trials) that are considered feasible for use in clinical106
practice and have sufficient validation. This allows a set or list of valid instruments from which107
practitioners may choose (i.e. a “pick and choose” list) to measure a particular domain.108
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This paper summarizes the progress made following the HOME roadmap for the HOME Clinical109
Practice Set and the recommendation on measurement of the most prioritized domain – symptoms110





We followed the HOME Clinical Practice Set Roadmaps Steps (Fig 1.). In brief, this included:115
Step 1: Define scope. To develop a set of the most suitable AE outcome measurement instruments116
to be used globally in clinical practice.117
Step 2: Develop a prioritized set of outcome domains. Utilizing an online survey of HOME members118
(Supplementary 1a)19, we outlined and prioritized the outcome domains to guide the work ahead119
(Fig. 2). Consistent with a previous HOME Delphi study,13 patient-reported symptoms was the120
highest prioritized domain to measure in patients with AE.121
Step 3; stages 1-2: identify instruments used to measure symptoms in AE and establish their122
extent and quality.123
Based on previous systematic reviews to identify instruments for measuring symptoms of AE and124
their measurement properties20,21 and applying an updated version of the latter (Supplementary125
1b19), 18 identified instruments were included. Based on best evidence synthesis, a recommendation126
for usage was provided for each instrument20 (Table 1).127
Table 1: Rating of symptoms instruments based on assessment of measurement properties20
Rating Criteria Instruments
A Meets all required quality items and is recommended for use None
B Meets two or more required quality items and has the
potential to be recommended in the future depending on the
results of further validation studies
Paediatric ISS, POEM, PO-
SCORAD, SA-EASI, adapted
SA-EASI
C Has low quality in at least one required quality criteria and
therefore is not recommended to be used any more
ADAM, EIQ, adult ISS, LIS,
SDQ, ZRADSQ
D Has (almost) not been validated. Its performance in all or most
relevant quality items is unclear, so that it is not recommended
to be used until further validation studies clarify its quality
ADQ, CoIQ, Method 4,
NESS, subjective SCORAD,
VAS itch, VRS itch
ADAM, Atopic Dermatitis Assessment Measure; ADQ, Atopic Dermatitis Quickscore; CoIQ, Web-based Characteristics of
Itch Questionnaire; EIQ, Eppendorf Itch Questionnaire; ISS, Itch Severity Scale; LIS, Leuven Itch Scale; NESS, Nottingham
Eczema Severity Score; POEM, Patient-Oriented Eczema Measure; PO-SCORAD, Patient-Oriented SCORing Atopic
Dermatitis index; SA-EASI, Self-administered Eczema Area and Severity Index; SCORAD, SCORing Atopic Dermatitis index;
SDQ, Skin Detective Questionnaire; VAS, Visual Analogue Scale; VRS, Verbal Rating Scale; ZRADSQ, Zheng-Related Atopic
Dermatitis Symptom Questionnaire.
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Step 3; stages 3-5: Selection of recommended instruments128
At the HOME VI meeting (Utrecht, the Netherlands, April 11th 2018), an international panel of 72129
participants (11 patients/parents of children with AE, 40 clinicians, 9 methodologists, and 12130
pharmaceutical industry representatives) focused on selecting recommended instruments.131
Consensus was reached if less than 30% of the voters disagreed.22 Those with a conflict of interest132
for a specific instrument were asked to refrain from voting.133
Consensus was reached that category C instruments, i.e. those that were shown to be low quality in134
at least one required quality criteria (Table 1), should be excluded from consideration.135
In the meeting, participants were presented with the remaining available instruments (ordered136
based on a pre-meeting prioritisation exercise, Supplementary 1c19) with their quality and feasibility137
attributes, followed by small-group (“whisper-technique”) and whole-panel discussions. Issues138
pertinent to the clinical practice settings were highlighted: selecting instruments that could be139
applied both by dermatologists and primary care providers; the importance of feasibility in the140
constrained setting of the day-to-day practice (including cost, accessibility, availability in multiple141
languages, and time to completion); and limiting the burden on patients.142
Consensus was reached on including the POEM and PO-SCORAD as instruments for assessing143
symptoms in the clinical practice setting (Supplementary 219). There was general agreement that144
while new-time users can take longer to complete the PO-SCORAD (up to 15 minutes), this improves145
with experience. The POEM takes 1 to 2 minutes to complete.23146
There was also general agreement on the need for a simple measure of itch intensity. The numerical147
rating scale for itch (NRS-itch) was discussed as an acceptable and feasible instrument.24 However,148
peer-reviewed validation studies for the NRS-itch in AE had not been published at the time of the149
meeting.25 Another limitation is that the optimal NRS-itch instrument for patients with AE has not150
been defined, including the recall period (i.e. the time over which itch is recalled) and whether the151
assessment should ask about “peak” versus “average” itch. Consensus was reached that an NRS for152
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itch intensity should be included in the HOME Clinical Practice Set for assessing symptoms. The153
specific instrument is yet to be defined and agreed upon. Of note, at the recent HOME VII meeting,154
the HOME group voted for a peak NRS with a 24-hour recall period as the preferred instrument to155






Following a pre-defined methodology delineated by the HOME Clinical Practice Set roadmap,161
building on systematic reviews and culminating in a consensus process driven by an international162
panel of multiple stakeholders including a significant contribution from patients, the POEM and the163
PO-SCORAD were selected as suitable instruments to measure symptoms in the clinical practice164
setting. The NRS-itch is a provisional instrument for measuring itch intensity, and will be addressed165
in future meetings as a validation study for an NRS-itch instrument in AE has become recently166
available.167
This is the first step in the HOME Clinical Practice Set effort to build a prioritized list of outcome168
domains with easy-to-use outcome measurement instruments for clinicians to “pick and choose”169
from in their daily clinical practice. We encourage clinicians and patients to apply at least one of the170
recommended instruments in their clinical practice, stressing that they should complement, not171
replace, a thorough history and physical examination. These instruments may be even more valuable172
when used in-between visits to provide a broader view of disease control and the patient symptom173
burden. They could also be filled in as patients are waiting to be seen in a hospital or community174
clinic, providing essential information for the assessing health care professional, and engaging the175
patient/family in the consultation before they enter the room. Both the POEM and the PO-SCORAD176
are free of charge, they are available in multiple languages and have unrestricted mobile apps177
(http://nottingham.ac.uk/research/groups/cebd/resources/poem.aspx;178
https://www.poscorad.com), all of which can facilitate their use.179
Validated data on the symptom burden of patients can improve patient care from the individual180
patient level to a clinic, hospital or national level. Data can be also collected and harmonized to181
provide for real-life research and quality improvement projects. Implementing PROs for the solo182
community practitioner may be challenging, however with dedicated resources and electronic183
medical record systems, large health systems have successfully implemented PROs into routine184
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primary care with the goals improving the patient experience and enhancing communication185
regarding their health status.27,28 Future work includes progressing on the assessing an NRS-itch186
instrument and addressing additional domains, starting with the patient global assessment187
prioritized by the group.188
189
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Abbreviation and acronym list190
AE: Atopic eczema191
COS: Core outcome set192
HOME: Harmonising Outcome Measures for Eczema193
NRS-itch: Numerical rating scale for itch194
PED-ISS: Pediatric Itch Severity Scale195
PO-SCORAD: Patient-Oriented SCORing Atopic Dermatitis index196
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Figure 1: The HOME roadmap for developing a set of outcome measurement instruments for clinical289
practice290
Figure 2: Results of the HOME Clinical Practice Set prioritization exercise – Percent of responders291





a. HOME online survey for developing a prioritized set of outcome domains
During April-May 2017, an online survey was distributed to HOME members (membership is free and
open to all) to characterize and prioritize the outcome domains for the HOME Clinical Practice Set. A
list of relevant domains was adapted from the original HOME Delphi exercise13 and additional
domains were elicited from HOME members in response to a membership-wide email. In the survey,
members were asked to rank their top 5 of 21 domains to prioritize for developing the Clinical
Practice Set. Overall there were 47 responders (30 clinicians, 9 patient representatives, 4
methodologists, 3 pharmaceutical industry representatives, and one health economist). The results
of this survey are depicted in Fig. 2. in the consensus paper.
b. Systematic review of the measurement properties of instruments for measuring symptoms of
AE update
A systematic review has previously been published by the HOME symptoms group for the clinical
trials COS (August 2015), evaluating 18 identified instruments.19 This review was updated for the
HOME Clinical Practice Set in February 2018 (paper to be submitted). The updated review included
six further validation studies (for POEM, Patient-Oriented SCORing Atopic Dermatitis (PO-SCORAD)
and the pediatric Itch Severity Scale (PED-ISS)). While the PED-ISS improved its rating on several
aspects of methodological quality and the POEM displayed poorer performance in some features,
there was no change in the overall degree of recommendation for each of the 18 instruments from
the original review.19
c. Pre-meeting online prioritisation exercise
For all category B and D instruments, HOME VI meeting registrants were provided with a copy of the
instrument and a summary of its properties. Each registrant was asked to classify each instrument as
i) definitely include, ii) possibly include or iii) definitely exclude from the Clinical Practice Set. A total
2
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of 46 out of 73 registered for the meeting (63%) completed the task. The results of the vote are
depicted in Supplementary table 1.
Supplementary table 1: Results of the pre-meeting task
* The subjective SCORAD, which was inadvertently not included in the pre-meeting voting, was added to
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